Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.

Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.

Tempest Therapeutics confirms an earlier success with its lead project, and this time investors respond.

The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.